Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Blood Advances|October 25, 2019
Pegylated interferon-2α invokes graft-versus-leukemia effects in patients relapsing after allogeneic stem cell transplantationAndrea S Henden, Antiopi Varelias, Justine Leach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2013
Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximabLuis Fayad, Fritz Offner, Mitchell R Smith, et al.
The Lancet. Haematology|December 3, 2017
Reduction of body iron in HFE-related haemochromatosis and moderate iron overload (Mi-Iron): a multicentre, participant-blinded, randomised controlled trialSim Y Ong, Lyle C Gurrin, Lara Dolling, et al.
Internal Medicine Journal|July 30, 2026
Allogeneic stem cell transplantation for mantle cell lymphoma can achieve durable remission and myeloablative conditioning is associated with inferior survival: an Australian and New Zealand Transplant & Cellular Therapies registry studySean McKeague, Pietro R Di Ciaccio, Steven Tran, et al.
Blood|January 29, 2021
A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxisGlen A Kennedy, Siok-Keen Tey, Luke Buizen, et al.
Leukemia Research|October 14, 2016
KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 studyRonan T Swords, Peter L Greenberg, Andrew H Wei, et al.
The Lancet. Haematology|January 27, 2020
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 studyJean-Jacques Kiladjian, Pierre Zachee, Masayuki Hino, et al.
BMJ Open|August 14, 2015
Should HFE p.C282Y homozygotes with moderately elevated serum ferritin be treated? A randomised controlled trial comparing iron reduction with sham treatment (Mi-iron)Sim Yee Ong, Lara Dolling, Jeannette L Dixon, et al.
Internal Medicine Journal|May 3, 2025
Outcomes of allogeneic haemopoietic transplant for chronic lymphocytic leukaemia in the modern eraLuani Barge, Steven Tran, Glen Kennedy, et al.
American Journal of Hematology|April 9, 2014
Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-upCarlo Gambacorti-Passerini, Tim H Brümmendorf, Dong-Wook Kim, et al.
Pageof 6